Is Exagen Stock a Good Investment?
Exagen Investment Advice | XGN |
- Examine Exagen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Exagen's leadership team and their track record. Good management can help Exagen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Exagen's business and its evolving consumer preferences.
- Compare Exagen's performance and market position to its competitors. Analyze how Exagen is positioned in terms of product offerings, innovation, and market share.
- Check if Exagen pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Exagen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Exagen Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Exagen Inc is a good investment.
Sell | Buy |
Sell
Market Performance | OK | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Exagen Stock
Researching Exagen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 28.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.12. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Exagen Inc recorded a loss per share of 1.09. The entity had not issued any dividends in recent years.
To determine if Exagen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exagen's research are outlined below:
| Exagen Inc may become a speculative penny stock | |
| Exagen Inc appears to be risky and price may revert if volatility continues | |
| Exagen Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 52.55 M. Reported Net Loss for the year was (23.69 M) with profit before taxes, overhead, and interest of 21.35 M. | |
| Exagen Inc has about 76.39 M in cash with (14.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Exagen Inc has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Why Fast-paced Mover Exagen Is a Great Choice for Value Investors |
Exagen Quarterly Cost Of Revenue |
|
Exagen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exagen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exagen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Exagen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Exagen's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-11 | 2020-03-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2021-08-09 | 2021-06-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2022-03-22 | 2021-12-31 | -0.5 | -0.42 | 0.08 | 16 | ||
2020-03-25 | 2019-12-31 | -0.37 | -0.27 | 0.1 | 27 | ||
2024-03-20 | 2023-12-31 | -0.43 | -0.31 | 0.12 | 27 | ||
2023-05-15 | 2023-03-31 | -0.56 | -0.44 | 0.12 | 21 | ||
2020-11-10 | 2020-09-30 | -0.47 | -0.34 | 0.13 | 27 | ||
2021-03-16 | 2020-12-31 | -0.41 | -0.27 | 0.14 | 34 |
Know Exagen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-03-31 | 62.5 K | Blackrock Inc | 2024-03-31 | 55.5 K | Renaissance Technologies Corp | 2024-03-31 | 48.8 K | Bridgeway Capital Management, Llc | 2024-03-31 | 40.8 K | State Street Corporation | 2024-03-31 | 27.7 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 26.4 K | Millennium Management Llc | 2024-03-31 | 23.9 K | Prudential Financial Inc | 2024-03-31 | 19.8 K | Palumbo Wealth Management Llc | 2024-03-31 | 18.2 K | Rtw Investments, Llc | 2024-03-31 | 1.5 M | Cowen And Company, Llc | 2024-03-31 | 898.6 K |
Exagen's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 34.05 M.Market Cap |
|
Exagen's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.51) | (0.53) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | (1.04) | (1.10) |
Determining Exagen's profitability involves analyzing its financial statements and using various financial metrics to determine if Exagen is a good buy. For example, gross profit margin measures Exagen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exagen's profitability and make more informed investment decisions.
The data published in Exagen's official financial statements typically reflect Exagen's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Exagen's quantitative information. For example, before you start analyzing numbers published by Exagen accountants, it’s essential to understand Exagen's liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Evaluate Exagen's management efficiency
Exagen Inc has Return on Asset of (0.1743) % which means that on every $100 spent on assets, it lost $0.1743. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6924) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of June 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Exagen's Debt To Assets are very stable compared to the past year. As of the 18th of June 2024, Fixed Asset Turnover is likely to grow to 9.61, while Total Assets are likely to drop about 54.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.28 | 1.35 | |
| Tangible Book Value Per Share | 1.28 | 1.35 | |
| Enterprise Value Over EBITDA | (1.08) | (1.14) | |
| Price Book Value Ratio | 1.55 | 1.18 | |
| Enterprise Value Multiple | (1.08) | (1.14) | |
| Price Fair Value | 1.55 | 1.18 | |
| Enterprise Value | 22.4 M | 27.9 M |
The analysis of Exagen's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Exagen's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Exagen Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.295 |
Basic technical analysis of Exagen Stock
As of the 18th of June 2024, Exagen shows the Semi Deviation of 3.39, mean deviation of 3.13, and Downside Deviation of 3.6. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Exagen, as well as the relationship between them.Exagen's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adawi Kamal over three weeks ago Disposition of 9297 shares by Adawi Kamal of Exagen at 1.9089 subject to Rule 16b-3 | ||
Adawi Kamal over three months ago Disposition of 3487 shares by Adawi Kamal of Exagen at 1.9099 subject to Rule 16b-3 | ||
John Aballi over three months ago Acquisition by John Aballi of 175000 shares of Exagen subject to Rule 16b-3 | ||
Tullis James L L over six months ago Exagen exotic insider transaction detected | ||
Tullis James L L over six months ago Purchase by Tullis James L L of 167 shares of Exagen |
Understand Exagen's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Exagen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0165 | |||
| Market Risk Adjusted Performance | 0.0543 | |||
| Mean Deviation | 3.13 | |||
| Semi Deviation | 3.39 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 8619.18 | |||
| Standard Deviation | 4.57 | |||
| Variance | 20.89 | |||
| Information Ratio | 0.0029 | |||
| Jensen Alpha | 0.0141 | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 0.0443 | |||
| Maximum Drawdown | 29.9 | |||
| Value At Risk | (5.03) | |||
| Potential Upside | 8.52 | |||
| Downside Variance | 12.94 | |||
| Semi Variance | 11.52 | |||
| Expected Short fall | (3.88) | |||
| Skewness | 1.58 | |||
| Kurtosis | 5.12 |
| Risk Adjusted Performance | 0.0165 | |||
| Market Risk Adjusted Performance | 0.0543 | |||
| Mean Deviation | 3.13 | |||
| Semi Deviation | 3.39 | |||
| Downside Deviation | 3.6 | |||
| Coefficient Of Variation | 8619.18 | |||
| Standard Deviation | 4.57 | |||
| Variance | 20.89 | |||
| Information Ratio | 0.0029 | |||
| Jensen Alpha | 0.0141 | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 0.0443 | |||
| Maximum Drawdown | 29.9 | |||
| Value At Risk | (5.03) | |||
| Potential Upside | 8.52 | |||
| Downside Variance | 12.94 | |||
| Semi Variance | 11.52 | |||
| Expected Short fall | (3.88) | |||
| Skewness | 1.58 | |||
| Kurtosis | 5.12 |
Consider Exagen's intraday indicators
Exagen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Exagen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Exagen time-series forecasting models is one of many Exagen's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Exagen's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Exagen Stock media impact
Far too much social signal, news, headlines, and media speculation about Exagen that are available to investors today. That information is available publicly through Exagen media outlets and privately through word of mouth or via Exagen internal channels. However, regardless of the origin, that massive amount of Exagen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Exagen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Exagen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Exagen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Exagen alpha.
Exagen Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Exagen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Exagen Corporate Management
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile | |
| Michael MD | Chief Officer | Profile |
Already Invested in Exagen Inc?
The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Information and Resources on Investing in Exagen Stock
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 3.134 | Quarterly Revenue Growth 0.284 | Return On Assets (0.17) | Return On Equity (0.69) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Exagen's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.